Savara Inc (SVRA NASDAQ) stock market data APIs
$2.1824
-0.02(-0.9%)
as of July 3, 2025
Try our APIs with
free plan!
Savara Inc Financial Data Overview
Price chart is built with
Anychart
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company was founded in 2007 and is headquartered in Langhorne, Pennsylvania.
Prev. Close
2.1824
Open
2.1613
High
2.2192
Low
2.0873
52 wk Range
1.89-5.11
Market Cap
379 M
Shares Outstanding
173 M
Revenue
1 000
EPS
-0.12
Beta
0.318
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Savara Inc data using free add-ons & libraries
Get Savara Inc Fundamental Data
Savara Inc Fundamental data includes:
- Net Revenue: 1 000
- EBITDA: -108 244 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-05-07
- EPS/Forecast: -0.128
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Savara Inc News
New
Savara Inc: director Hawkins buys $98k in shares
Director Richard J Hawkins (NASDAQ:HWKN) of Savara Inc (NASDAQ:SVRA), a $441 million market cap biotechnology company, acquired 48,225 shares of common stock on June 20, 2025, according to a Form 4 ...
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Savara Inc. – SVRA
NEW YORK, June 23, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Savara Inc. (“Savara” or the “Company”) (NASDAQ: SVRA). Such investors are advised...
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Savara Inc. - SVRA
NEW YORK, June 18, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Savara Inc. (“Savara” or the “Company”) (NASDAQ: SVRA). Such investors are advis...
Savara's SWOT analysis: biotech firm's stock poised for growth with aPAP drug
Savara Inc. (NASDAQ:SVRA), a biotechnology company specializing in rare respiratory diseases with a market capitalization of $466 million, is poised for a potential breakthrough with its lead candidat...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
